Case #17: Every Cure Pt.1 (Dr. David Fajgenbaum)
Digest
David, a healthy medical student, experienced sudden debilitating fatigue, swelling, and rashes. His initial diagnosis was delayed, causing a rapid decline in his health and multiple hospitalizations. Doctors eventually diagnosed him with Castleman disease, a rare and often fatal condition, giving a grim prognosis. After months of unsuccessful treatments, a lymph node biopsy revealed an aggressive subtype. He endured relapses, hospitalizations, and chemotherapy. Reaching a breaking point, David shifted from patient to researcher, testing experimental drugs, including Sirolimus, an mTOR inhibitor. After a long remission, Sirolimus proved effective. His wedding symbolized resilience, and his remission inspired him to continue research, collaborating with others to find a cure for Castleman disease. His story highlights the potential of off-label drug use and collaborative research in tackling rare diseases.
Outlines
Diagnosis and Initial Struggle with Castleman Disease
David, a healthy medical student, faces sudden severe illness, initially misdiagnosed, leading to rapid health decline and multiple hospitalizations before a diagnosis of Castleman disease, a rare and often fatal condition, is reached.
Aggressive Treatment and Relapse
David's aggressive subtype of Castleman disease necessitates intense treatment, including chemotherapy, resulting in multiple relapses and near-death experiences.
From Patient to Researcher: The Search for a Cure
Driven by his near-death experiences, David transitions from patient to researcher, actively collaborating with experts globally to find a cure for Castleman disease and testing experimental treatments.
Sirolimus and Remission
David's research leads him to Sirolimus, an mTOR inhibitor, which proves effective in controlling his disease, leading to a long period of remission.
Renewed Purpose and Continued Research
David's remission inspires him to continue his research and collaboration efforts, aiming to help others battling Castleman disease and contributing to future treatment strategies.
Keywords
Castleman Disease
A rare and serious disorder causing the immune system to overreact, attacking the body's own tissues and organs. Symptoms include fatigue, swelling, and organ failure. Treatment options are limited, and prognosis depends on the subtype.
mTOR inhibitor
A class of drugs that block the mTOR pathway, crucial in cell growth and immune responses. Used to treat cancers and autoimmune diseases. Sirolimus, an example, showed promise in treating Castleman disease.
Sirolimus
An mTOR inhibitor that proved effective in controlling David's aggressive Castleman disease, leading to long-term remission.
Off-label drug use
Using a medication approved for one condition to treat another, often done when standard treatments fail. David's case highlights its potential.
Rare Disease Research
The challenges and successes of researching and treating rare diseases like Castleman disease, emphasizing collaborative efforts and innovative approaches.
Q&A
What were the initial symptoms that led David to seek medical attention?
Extreme fatigue, swelling in his ankles, lumps in his neck, and rashes.
What made David's case of Castleman disease particularly challenging to treat?
He had a rare and aggressive subtype, rendering standard treatments ineffective and leading to rapid deterioration.
How did David's personal experience influence his approach to finding a cure?
Near-death experiences and witnessing his mother's cancer battle drove him to become a researcher, actively pursuing treatments and collaborating with experts.
What role did Sirolimus play in David's recovery?
Sirolimus, an mTOR inhibitor, controlled his Castleman disease after other treatments failed, resulting in long-term remission.
What is the significance of David's story for future research into Castleman disease?
It highlights the potential of off-label drug use and collaborative research in tackling rare diseases, offering valuable insights for future studies.
Show Notes
Dr. David Fajgenbaum, once a college quarterback and competitive weightlifter, turned medical researcher, was the picture of health until he became critically ill at the age of 25. After all available treatments failed to keep him out of the ICU, David, with his friend Grant’s help, races to save his own life, repurposing existing drugs to find a cure.
*
*
*
*
*
*
****** SPOILER ALERT BELOW ******
If you’re looking for information on Castleman disease or if would like to find out more about the work of Grant, David, and the Every Cure team, visit EveryCure.org.
See omnystudio.com/listener for privacy information.
Table of contents
United States
